Literature DB >> 29728712

[Hemorrhage under direct oral anticoagulants : Occurrence and treatment in intensive care patients].

H M Hoffmeister1, H Darius2, M Buerke3,4.   

Abstract

The use of anticoagulants is associated with an increased risk of bleeding and nevertheless bleeding complications can be lifethreatening. The focus is on bleeding under direct oral anticoagulants (DOAC) because antidotes and specific measures are lacking for some DOACs. Furthermore, routinely carried out clotting tests cannot be used to determine the degree of anticoagulation under DOACs. Therefore, it becomes difficult to determine whether the coagulation inhibition effect is present. This article presents the treatment of hemorrhage in patients with DOACs in the intensive care unit. Further, the indications for DOACS and details of administration and monitoring are presented.

Entities:  

Keywords:  Apixaban; Blood coagulation; Blood coagulation factors; Dabigatran; Edoxaban; Hematologic agents; Rivaroxaban

Mesh:

Substances:

Year:  2018        PMID: 29728712     DOI: 10.1007/s00063-018-0436-8

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  46 in total

1.  Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin.

Authors:  Ronald L Koretz
Journal:  Ann Intern Med       Date:  2015-09-15       Impact factor: 25.391

2.  Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.

Authors:  Dolly A Parasrampuria; Thomas Marbury; Nobujo Matsushima; Shuquan Chen; Prachi K Wickremasingha; Ling He; Victor Dishy; Karen S Brown
Journal:  Thromb Haemost       Date:  2015-01-08       Impact factor: 5.249

3.  The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa.

Authors:  K T Htun; J McFadyen; H A Tran
Journal:  Ann Hematol       Date:  2014-03-02       Impact factor: 3.673

4.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 5.  2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Authors:  Gordon F Tomaselli; Kenneth W Mahaffey; Adam Cuker; Paul P Dobesh; John U Doherty; John W Eikelboom; Roberta Florido; William Hucker; Roxana Mehran; Steven R Messé; Charles V Pollack; Fatima Rodriguez; Ravindra Sarode; Deborah Siegal; Barbara S Wiggins
Journal:  J Am Coll Cardiol       Date:  2017-12-01       Impact factor: 24.094

Review 6.  New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

Authors:  Francesco Scaglione
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 7.  Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.

Authors:  C Chai-Adisaksopha; C Hillis; T Isayama; W Lim; A Iorio; M Crowther
Journal:  J Thromb Haemost       Date:  2015-10-05       Impact factor: 5.824

8.  Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.

Authors:  Lisa E Dumkow; Johnathan R Voss; Michael Peters; Douglas L Jennings
Journal:  Am J Health Syst Pharm       Date:  2012-10-01       Impact factor: 2.637

9.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

10.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.